Here is a link which outlines the two different trials:
http://www.nationalmssociety.org/site/P ... h_2007nov2
What I really found interesting is Biogen comparing this new oral drug in the one trial to patients using Copaxone. In my opinion, there can only be one reason for doing this....trying to prove that this new drug is better than Copaxone (competitive drug to Biogen's Avcnex and Tysabri )and thus hopefully gaining some market share in the very competitive MS drug world.
The Phase II trials of Fumarate supposedly showed a 69% drop in active MS brain lesions vs placebo as seen on MRI's. Having said that, we know that there is little or no correlation between brain lesions and MS symptoms or disease progression. I don't have MS but if I did, I'm not so sure that I would take a chance with something this new and unproven. I would certainly be sitting down and talking to my neuro about it, getting his/her opinion and doing as much research as possible before making a final decision.